US2009029995A1PendingUtilityA1
Hetero biaryl derivatives as matrix metalloproteinase inhibitors
Est. expiryAug 13, 2022(expired)· nominal 20-yr term from priority
A61P 9/10A61P 35/00A61P 9/04A61P 9/00A61P 43/00A61P 27/02A61P 25/00A61P 29/00A61P 17/06A61P 19/00A61P 11/00A61P 1/04A61P 19/10A61P 19/02A61P 11/06C07D 401/12C07D 409/06C07D 413/10C07D 271/107C07D 233/56C07D 417/10C07D 405/12C07D 401/14C07D 231/12C07D 401/04C07D 401/06C07D 249/08C07D 271/10C07D 403/06C07D 285/12C07D 257/04C07D 417/12
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, S, T, U, V, and R 2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.
Claims
exact text as granted — not AI-modified1 . A compound of Formula I
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 and R 2 independently are selected from:
H;
C 1 -C 6 alkyl;
Substituted C 1 -C 6 alkyl;
C 2 -C 6 alkenyl;
Substituted C 2 -C 6 alkenyl;
C 2 -C 6 alkynyl;
Substituted C 2 -C 6 alkynyl;
C 3 -C 6 cycloalkyl;
Substituted C 3 -C 6 cycloalkyl;
C 3 -C 6 cycloalkyl-(C 1 -C 6 alkylenyl);
Substituted C 3 -C 6 cycloalkyl-(C 1 -C 6 alkylenyl);
3- to 6-membered heterocycloalkyl;
Substituted 3- to 6-membered heterocycloalkyl;
3- to 6-membered heterocycloalkyl-(C 1 -C 6 alkylenyl);
Substituted 3- to 6-membered heterocycloalkyl-(C 1 -C 6 alkylenyl);
Phenyl-(C 1 -C 6 alkylenyl);
Substituted phenyl-(C 1 -C 6 alkylenyl);
Naphthyl-(C 1 -C 6 alkylenyl);
Substituted naphthyl-(C 1 -C 6 alkylenyl);
5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Substituted 5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Phenyl;
Substituted phenyl;
Naphthyl;
Substituted naphthyl;
5-, 6-, 9-, and 10-membered heteroaryl;
Substituted 5-, 6-, 9-, and 10-membered heteroaryl;
R 3 O—(C 1 -C 6 alkylenyl);
Substituted R 3 O—(C 1 -C 6 alkylenyl);
5- or 6-membered heteroaryl;
Substituted 5- or 6-membered heteroaryl;
8- to 10-membered heterobiaryl;
Substituted 8- to 10-membered heterobiaryl;
Phenyl-O—(C 1 -C 8 alkylenyl);
Substituted phenyl-O—(C 1 -C 8 alkylenyl);
Phenyl-S—(C 1 -C 8 alkylenyl);
Substituted phenyl-S—(C 1 -C 8 alkylenyl);
Phenyl-S(O)—(C 1 -C 8 alkylenyl);
Substituted phenyl-S(O)—(C 1 -C 8 alkylenyl);
Phenyl-S(O) 2 —(C 1 -C 8 alkylenyl); and
Substituted phenyl-S(O) 2 —(C 1 -C 8 alkylenyl);
wherein R 1 and R 2 are not both selected from:
H;
C 1 -C 6 alkyl;
C 2 -C 6 alkenyl;
C 2 -C 6 alkynyl; and
C 3 -C 6 cycloalkyl;
Each R 3 independently is selected from:
H;
C 1 -C 6 alkyl;
Substituted C 1 -C 6 alkyl;
C 3 -C 6 cycloalkyl;
Substituted C 3 -C 6 cycloalkyl;
Phenyl-(C 1 -C 6 alkylenyl);
Substituted phenyl-(C 1 -C 6 alkylenyl);
Naphthyl-(C 1 -C 6 alkylenyl);
Substituted naphthyl-(C 1 -C 6 alkylenyl);
5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Substituted 5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Phenyl;
Substituted phenyl;
Naphthyl;
Substituted naphthyl;
5-, 6-, 9-, and 10-membered heteroaryl;
Substituted 5-, 6-, 9-, and 10-membered heteroaryl;
S, T, U, and W each are C—R 4 ; or
One of S, T, U, and W is N and the other three of S, T, U, and W are C—R 4 ; or
Two of S, T, U, and W are N and the other two of S, T, U, and W are C—R 4 ; or
T is C—R 4 and S, U, and W are each N; or
U is C—R 4 and S, T, and W are each N; or
S is C—R 4 and T, U, and W are each N;
Each R 4 independently is selected from:
H;
F;
CH 3 ;
CF 3 ;
C(O)H;
CN;
HO;
CH 3 O;
C(F)H 2 O;
C(H)F 2 O; and
CF 3 O;
V is a 5-membered heteroarylenyl; and Q is selected from:
OCH 2 ;
N(R 6 )CH 2 ;
OC(O);
CH(R 6 )C(O);
OC(NR 6 );
CH(R 6 )C(NR 6 );
N(R 6 )C(O);
N(R 6 )C(S);
N(R 6 )C(NR 6 );
N(R 6 )CH 2 ;
SC(O);
CH(R 6 )C(S);
SC(NR 6 );
trans-(H)C═C(H);
cis-(H)C═C(H);
C≡C;
CH 2 C≡C;
C≡CCH 2 ;
CF 2 C≡C;
C≡CCF 2 ;
or V is C(O)O, C(S)O, C(O)N(R 5 ), or C(S)N(R 5 ); and Q is selected from:
OCH 2 ;
N(R 6 )CH 2 ;
CH(R 6 )C(O);
OC(NR 6 );
CH(R 6 )C(NR 6 );
N(R 6 )C(NR 6 );
N(R 6 )CH 2 ;
CH(R 6 )C(S);
SC(NR 6 );
trans-(H)C═C(H);
cis-(H)C═C(H);
C≡CCH 2 ;
C≡CCF 2 ;
R 5 is H or C 1 -C 6 alkyl;
R 6 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;
X is O, S, N(H), or N(C 1 -C 6 alkyl);
Each V 1 is independently C(H) or N;
Each “substituted” group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:
C 1 -C 6 alkyl;
C 2 -C 6 alkenyl;
C 2 -C 6 alkynyl;
C 3 -C 6 cycloalkyl;
C 3 -C 6 cycloalkylmethyl;
Phenyl;
Phenylmethyl;
3- to 6-membered heterocycloalkyl;
3- to 6-membered heterocycloalkylmethyl;
cyano;
CF 3 ;
(C 1 -C 6 alkyl)-OC(O);
HOCH 2 ;
(C 1 -C 6 alkyl)-OCH 2 ;
H 2 NCH 2 ;
(C 1 -C 6 alkyl)-N(H)CH 2 ;
(C 1 -C 6 alkyl) 2 -NCH 2 ;
N(H) 2 C(O);
(C 1 -C 6 alkyl)-N(H)C(O);
(C 1 -C 6 alkyl) 2 -NC(O);
N(H) 2 C(O)N(H);
(C 1 -C 6 alkyl)-N(H)C(O)N(H);
N(H) 2 C(O)N(C 1 -C 6 alkyl);
(C 1 -C 6 alkyl)-N(H)C(O)N(C 1 -C 6 alkyl);
(C 1 -C 6 alkyl) 2 -NC(O)N(H);
(C 1 -C 6 alkyl) 2 -NC(O)N(C 1 -C 6 alkyl);
N(H) 2 C(O)O;
(C 1 -C 6 alkyl)-N(H)C(O)O;
(C 1 -C 6 alkyl) 2 -NC(O)O;
HO;
(C 1 -C 6 alkyl)-O;
CF 3 O;
CF 2 (H)O;
CF(H) 2 O;
H 2 N;
(C 1 -C 6 alkyl)-N(H);
(C 1 -C 6 alkyl) 2 -N;
O 2 N;
(C 1 -C 6 alkyl)-S;
(C 1 -C 6 alkyl)-S(O);
(C 1 -C 6 alkyl)-S(O) 2 ;
(C 1 -C 6 alkyl) 2 -NS(O) 2 ;
(C 1 -C 6 alkyl)-S(O) 2 —N(H)—C(O)—(C 1 -C 8 alkylenyl) m ; and
(C 1 -C 6 alkyl)-C(O)—N(H)—S(O) 2 —(C 1 -C 8 alkylenyl) m ;
wherein each substituent on a carbon atom may further be independently selected from:
Halo;
HO 2 C; and
OCH 2 O, wherein each 0 is bonded to adjacent carbon atoms to form a 5-membered ring;
wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C═O;
wherein two adjacent, substantially sp 2 carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:
R is H or C 1 -C 6 alkyl;
m is an integer of 0 or 1;
wherein each 5-membered heteroarylenyl independently is a 5-membered ring containing carbon atoms and from 1 to 4 heteroatoms selected from 1 O, 1 S, 1 NH, 1 N(C 1 -C 6 alkyl), and 4 N, wherein the O and S atoms are not both present, and wherein the heteroarylenyl may optionally be unsubstituted or substituted with 1 substituent selected from fluoro, methyl, hydroxy, trifluoromethyl, cyano, and acetyl;
wherein each heterocycloalkyl is a ring that contains carbon atoms and 1 or 2 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O) 2 , 1 N, 2 N(H), and 2 N(C 1 -C 6 alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;
wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C 1 -C 6 alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N,N(H), and N(C 1 -C 6 alkyl), and 5- and 6-membered heteroaryl are monocyclic rings; and 9- and 10-membered heteroaryl are 6,5-fused and 6,6-fused bicyclic rings, respectively, wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other;
wherein with any (C 1 -C 6 alkyl) 2 -N group, the C 1 -C 6 alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and
wherein each group and each substituent recited above is independently selected.
2 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein V is a 5-membered heteroarylenyl; and Q is N(H)C(O).
3 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein S is N and T, U, and W each are C—R 4 ; V is a 5-membered heteroarylenyl; and Q is N(H)C(O).
4 . The compound according to claims 2 or 3 , or a pharmaceutically acceptable salt thereof, wherein at least one of R 1 and R 2 is independently selected from:
Phenyl-(C 1 -C 6 alkylenyl); and Substituted phenyl-(C 1 -C 6 alkylenyl); wherein each group and each substituent is independently selected.
5 . The compound according to claims 2 or 3 , or a pharmaceutically acceptable salt thereof, wherein at least one of R 1 and R 2 is independently selected from:
5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl); and Substituted 5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl); wherein each heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C 1 -C 6 alkyl), and 4 N, and 5- and 6-membered heteroaryl are monocyclic rings and 9- and 10-membered heteroaryl are 6,5-fused and 6,6-fused bicyclic rings, respectively, wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other; and wherein each group and each substituent is independently selected.
6 . The compound according to claim 4 , or a pharmaceutically acceptable salt thereof, wherein each C 1 -C 6 alkylenyl is CH 2 , C(CH 3 ) 2 , C(═O), or CF 2 .
7 . The compound according to claim 6 , or a pharmaceutically acceptable salt thereof, wherein each C 1 -C 6 alkylenyl is CH 2 .
8 . The compound according to claim 5 , or a pharmaceutically acceptable salt thereof, wherein each C 1 -C 6 alkylenyl is CH 2 , C(CH 3 ) 2 , C(═O), or CF 2 .
9 . The compound according to claim 8 , or a pharmaceutically acceptable salt thereof, wherein each C 1 -C 6 alkylenyl is CH 2 .
10 . The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula Ia
or a pharmaceutically acceptable salt thereof,
wherein:
R 1 and R 2 independently are selected from:
Substituted C 1 -C 6 alkyl;
Substituted C 2 -C 6 alkenyl;
Substituted C 2 -C 6 alkynyl;
Substituted C 3 -C 6 cycloalkyl;
Substituted C 3 -C 6 cycloalkyl-(C 1 -C 6 alkylenyl);
Substituted 3- to 6-membered heterocycloalkyl;
Substituted 3- to 6-membered heterocycloalkyl-(C 1 -C 6 alkylenyl);
Phenyl-(C 1 -C 6 alkylenyl);
Substituted phenyl-(C 1 -C 6 alkylenyl);
5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Substituted 5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Phenyl;
Substituted phenyl;
5-, 6-, 9-, and 10-membered heteroaryl;
Substituted 5-, 6-, 9-, and 10-membered heteroaryl;
R 3 O—(C 1 -C 6 alkylenyl);
Substituted R 3 O—(C 1 -C 6 alkylenyl);
Naphthyl;
Substituted naphthyl;
5- or 6-membered heteroaryl;
Substituted 5- or 6-membered heteroaryl;
8- to 10-membered heterobiaryl;
Substituted 8- to 10-membered heterobiaryl;
Phenyl-O—(C 1 -C 8 alkylenyl);
Substituted phenyl-O—(C 1 -C 8 alkylenyl);
Phenyl-S—(C 1 -C 8 alkylenyl);
Substituted phenyl-S—(C 1 -C 8 alkylenyl);
Phenyl-S(O)—(C 1 -C 8 alkylenyl);
Substituted phenyl-S(O)—(C 1 -C 8 alkylenyl);
Phenyl-S(O) 2 —(C 1 -C 8 alkylenyl); and
Substituted phenyl-S(O) 2 —(C 1 -C 8 alkylenyl);
Each R 3 independently is selected from:
Substituted C 1 -C 6 alkyl;
Substituted C 3 -C 6 cycloalkyl;
Phenyl-(C 1 -C 6 alkylenyl);
Substituted phenyl-(C 1 -C 6 alkylenyl);
5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
Substituted 5-, 6-, 9-, and 10-membered heteroaryl-(C 1 -C 6 alkylenyl);
5-, 6-, 9-, and 10-membered heteroaryl;
Substituted 5-, 6-, 9-, and 10-membered heteroaryl;
S, T, U, and W each are C—R 4 ; or
One of S, T, U, and W is N and the other three of S, T, U, and W are C—R 4 ; or
Two of S, T, U, and W are N and the other two of S, T, U, and W are C—R 4 ; or
T is C—R 4 and S, U, and W are each N; or
U is C—R 4 and S, T, and W are each N; or
S is C—R 4 and T, U, and W are each N;
Each R 4 independently is selected from: H, F, CH 3 , CF 3 , C(O)H, CN, HO, CH 3 O, C(F)H 2 O, C(H)F 2 O, and CF 3 O;
V is a 5-membered heteroarylenyl; and Q is selected from: OCH 2 , N(R 6 )CH 2 , OC(O), CH(R 6 )C(O), OC(NR 6 ), CH(R 6 )C(NR 6 ), N(R 6 )C(O), N(R 6 )C(S), N(R 6 )C(NR 6 ), N(R 6 )CH 2 , SC(O), CH(R 6 )C(S), SC(NR 6 ), trans-(H)C═C(H), cis-(H)C═C(H), C≡C, CH 2 C≡C, C≡CCH 2 , CF 2 C≡C, C≡CCF 2 ,
or V is C(O)O, C(S)O, C(O)N(R 5 ), or C(S)N(R 5 ); and Q is selected from: OCH 2 , N(R 6 )CH 2 , CH(R 6 )C(O), OC(NR 6 ), CH(R 6 )C(NR 6 ), N(R 6 )C(NR 6 ), N(R 6 )CH 2 , CH(R 6 )C(S), SC(NR 6 ), trans-(H)C═C(H), cis-(H)C═C(H), C≡CCH 2 , C≡CCF 2 ,
R 5 is H or C 1 -C 6 alkyl;
R 6 is H, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;
X is O, S, N(H), or N(C 1 -C 6 alkyl);
Each V 1 is independently C(H) or N;
Each “substituted” group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:
C 1 -C 6 alkyl;
C 2 -C 6 alkenyl;
C 2 -C 6 alkynyl;
C 3 -C 6 cycloalkyl;
C 3 -C 6 cycloalkylmethyl;
Phenyl;
Phenylmethyl;
3- to 6-membered heterocycloalkyl;
3- to 6-membered heterocycloalkylmethyl;
cyano;
CF 3 ;
(C 1 -C 6 alkyl)-OC(O);
HOCH 2 ;
(C 1 -C 6 alkyl)-OCH 2 ;
H 2 NCH 2 ;
(C 1 -C 6 alkyl)-N(H)CH 2 ;
(C 1 -C 6 alkyl) 2 -NCH 2 ;
N(H) 2 C(O);
(C 1 -C 6 alkyl)-N(H)C(O);
(C 1 -C 6 alkyl) 2 -NC(O);
N(H) 2 C(O)N(H);
(C 1 -C 6 alkyl)-N(H)C(O)N(H);
N(H) 2 C(O)N(C 1 -C 6 alkyl);
(C 1 -C 6 alkyl)-N(H)C(O)N(C 1 -C 6 alkyl);
(C 1 -C 6 alkyl) 2 -NC(O)N(H);
(C 1 -C 6 alkyl) 2 -NC(O)N(C 1 -C 6 alkyl);
N(H) 2 C(O)O;
(C 1 -C 6 alkyl)-N(H)C(O)O;
(C 1 -C 6 alkyl) 2 -NC(O)O;
HO;
(C 1 -C 6 alkyl)-O;
CF 3 O;
CF 2 (H)O;
CF(H) 2 O;
H 2 N;
(C 1 -C 6 alkyl)-N(H);
(C 1 -C 6 alkyl) 2 -N;
O 2 N;
(C 1 -C 6 alkyl)-S;
(C 1 -C 6 alkyl)-S(O);
(C 1 -C 6 alkyl)-S(O) 2 ;
(C 1 -C 6 alkyl) 2 -NS(O) 2 ;
(C 1 -C 6 alkyl)-S(O) 2 —N(H)—C(O)—(C 1 -C 8 alkylenyl) m ;
(C 1 -C 6 alkyl)-C(O)—N(H)—S(O) 2 —(C 1 -C 8 alkylenyl) m ;
HO—C(═O)—(C 1 -C 3 alkylenyl);
HO—C(═O)—(C 3 -C 6 cycloalkylen-1-yl);
Phenyl substituted with 1 or two substituents selected from F, Cl, OH, OCH 3 , C≡N, COOH, COOCH 3 , C(═O)CH 3 , and CF 3 ;
5- or 6-membered heteroaryl;
5- or 6-membered heteroaryl substituted with 1 substituent selected from F, Cl, OH, OCH 3 , C≡N, COOH, COOCH 3 , C(═O)CH 3 , and CF 3 ;
SO 3 H;
PO 3 H 2 ; and
R 7 R 7a -(J) m -N(H)CH 2 , wherein m is an integer of 0 or 1; J is N—C(═O); and R 7 and R 7a are independently selected from hydrogen, C 1 -C 6 alkyl, (C 1 -C 6 alkyl)-C(═O), C 1 -C 6 alkyl substituted with 1 or 2 OH, C 1 -C 3 alkyl-O—(C 1 -C 3 alkylenyl), 5- or 6-membered heteroaryl-C(═O), and (C 1 -C 6 alkyl)-S(O) 2 ; or R 7 and R 7a may be taken together with the nitrogen atom to which they are both bonded to form (i) a 3- to 6-membered heterocycloalkyl, optionally substituted with a CH 3 or oxo (i.e., ═O), containing the nitrogen atom, 0 or 10 or S atoms, and carbon atoms or (ii) a 5- or 6-membered heteroaryl containing the nitrogen atom, 0 or 1 additional N atom, and carbon atoms;
wherein each substituent on a carbon atom may further be independently selected from:
Halo;
HO 2 C; and
OCH 2 O, wherein each O is bonded to adjacent carbon atoms to form a 5-membered ring;
wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C═O;
wherein two adjacent, substantially sp 2 carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:
R is H or C 1 -C 6 alkyl;
m is an integer of 0 or 1;
wherein each 5-membered heteroarylenyl independently is a 5-membered ring containing carbon atoms and from 1 to 4 heteroatoms selected from 1 O, 1 S, 1 NH, 1 N(C 1 -C 6 alkyl), and 4 N, wherein the O and S atoms are not both present, and wherein the heteroarylenyl may optionally be unsubstituted or substituted with 1 substituent selected from fluoro, methyl, hydroxy, trifluoromethyl, cyano, and acetyl;
wherein each heterocycloalkyl is a ring that contains carbon atoms and 1 or 2 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O) 2 , 1 N, 2 N(H), and 2 N(C 1 -C 6 alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;
wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C 1 -C 6 alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N,N(H), and N(C 1 -C 6 alkyl), and 5- and 6-membered heteroaryl are monocyclic rings; and 9- and 10-membered heteroaryl are 6,5-fused and 6,6-fused bicyclic rings, respectively, wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each other;
wherein with any (C 1 -C 6 alkyl) 2 -N group, the C 1 -C 6 alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and
wherein each group and each substituent recited above is independently selected.
11 . The compound according to claim 10 , or a pharmaceutically acceptable salt thereof, wherein S, T, U, and W are each CH or one of S, T, U, and W is N and the other three of S, T, U, and W are each CH; and Q is C≡C or N(R 6 )C(O).
12 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.Join the waitlist — get patent alerts
Track US2009029995A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.